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Available online 26 May 2016Background: Desmoplastic small round cell tumor (DSRCT) is an extremely rare sarcomatous tumor, which is
most commonly seen in men. Clinicians managing a patient with a rapidly enlarging mass in pregnancy should
be aware of the risk for malignancy.
Case: A 31-year-old woman was found to have a newly enlarged ovarian mass in the second trimester. She sub-
sequently underwent a laparotomy for removal, with chemotherapy for presumed poorly differentiated ovarian
malignancy. Ultimately she was diagnosedwith a desmoplastic small round cell tumor of the ovary and had pro-
gression at time of delivery. Following cesarean delivery, she had a tumor reductive surgery. She has completed
12 cycles of intensive chemotherapy and is alive with disease at 14 months.
Conclusion: Care should be taken not to delay evaluation of a rapidly enlarging mass in pregnancy. While this
tumor type is extremely rare, a malignancy in pregnancy must be ruled out in this clinical scenario.





ChemotherapyAdnexal mass in pregnancy is an uncommon, but not rare occur-
rence with approximately 1 in 600 pregnancies being affected. Rapidly
enlarging masses, a mass N 8 cm in size, and those with complex fea-
tures warrant surgical intervention in pregnancy. This is not only to
rule out malignancy, but also to avoid acute complications like ovarian
torsion (Horowitz, 2011). Most often these newly diagnosed adnexal
masses are benign (Smith et al., 2001).
In contrary, newly diagnosed ovarian malignancy in pregnancy is
exceedingly rare, with estimated rate of 1 in 10,000 pregnancies
(Leiserowitz et al., 2006). Tumors arising in the ovary during pregnancy
are most often early-stage germ cell, sex-cord stromal, or borderline
tumors. Rarely will an advanced epithelial lesion be encountered, and
this is related to age of onset (Leiserowitz et al., 2006). With the relative
rarity of this event, a high index of suspicion is warranted in pelvic
masses that display aggressive features.
We present a case of a newly diagnosed rare sarcoma arising from
the ovary that was successfully removed antepartum, and with a short
interval recurrence prior to delivery.
Case: A 31-year-old woman, gravida 2 para 1, presented to her OB
ofﬁce for routine ﬁrst prenatal visit at 7 weeks gestational age. A pelvic
exam was completed without any adnexal pathology and she
underwent a dating trans-vaginal ultrasound which showed a 7-weekStarling Loving Hall, Columbus,
. This is an open access article underfetal pole with cardiac activity; as well as normal adnexa with the
right ovary measuring 2.8 cm × 2.5 cm and the left ovary measuring
3.16 cm × 2.95 cm.
Her obstetric history consisted of one prior cesarean delivery at
37 weeks due to mild pre-eclampsia. She reported no history of abnor-
mal Pap smear or sexually transmitted infection. She did have a past
history of oral contraceptive pill use. She denied any family history of
breast, ovarian, cervical, uterine, or colorectal cancer.
On routine anatomy ultrasound at 19weeks shewas noted to have a
large 10.8 × 11.6 × 10.5 cm lobular, heterogeneous mass in the right
adnexa. Repeat ultrasound at 23w0d showed marked enlargement of
themass now to at least 17×18×10.7 cm.Maternal fetalmedicine con-
sultation recommended an abdominal/pelvic MRI to better characterize
the mass. In addition, she was initiated on labetalol due to continued
elevations in her blood pressure. The pregnancy was also complicated
with type A2 gestational diabetes mellitus.
A non-contrast MRI of the abdomen and pelvis revealed a
20.5 × 12 × 16.3 cm mass in the right adnexa, abutting the uterus, and
not separate from the ovary (Fig. 1). The left ovary appeared anatomi-
cally normal. There was also lymphadenopathy adjacent to the IVC
and aorta measuring 2.6 × 1.9 cm.
Following the MRI, the patient completed a consultation with
gynecologic oncology. Tumor markers drawn showed a CA-125 was
89U/mL, AFPwas 137 ng/mL, and Inhibin A/Bwerewithin normal levels.
The patient underwent exploratory laparotomy at 27w2d gestation.
Continuous fetal monitoringwas completed during this procedure withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Non-contrast coronal T2 image showing the large heterogeneous mass abutting the uterus with the fetal head in view (arrows).
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right ovary and tube, which was described as a 20 cm right adnexal
mass that entirely replaced the ovary (Fig. 2). Frozen section of the
tumorwas reported as a granulosa cell tumor. Amodiﬁed stagingproce-
dure then took place to include a partial omentectomy, as well as
debulking a large isolated 5 × 3 cm pre-caval lymph node. Fetal well-
beingwas reassuring throughout the procedure. There was no evidence
of disease elsewhere on peritoneal surfaces, uterine body, or left ovary.
Her post-operative coursewas complicated by a post-operative ileus
which requiredNG tubemanagement for resolution. She also developed
leukopenia during her hospitalization,whichwas thought to be second-
ary to medication effect, possibly from an Indocin course she was given
for tocolysis following the procedure. Her leukopenia recovered prior
to discharge. Shewas also anemic following surgery andwas transfused
two units of packed red blood cells prior to discharge. She was
discharged home on post-operative day 6 in stable condition.Fig. 2. Gross image of tumor obliterating normal ovary removed at 27 weeks gestation.The initial pathology report of the tumor yielded a diagnosis of poor-
ly differentiated carcinoma of unknown primary. The tumor described
histologically is as follows: right ovary is replaced by a poorly-differen-
tiated malignant neoplasm, characterized by sheets, nests and cords of
pleomorphic cells within a ﬁbrous stromal background (Fig. 3). The
tumor immunohistochemistry was inconclusive. Tumor tissue was
sent for review by an expert pathologist. While further staining did
not yield a deﬁnitive diagnosis, the expert pathologist recommended
the tumor be sent for FISH analysis.
Completion of metastatic work up included a CT of her chest and a
breast mammogram. The chest CT was negative for metastasis and a
mass noted onmammogramwasnegative on biopsy. At 30w3ddecision
was made to initiate chemotherapy for presumed stage III poorly
differentiated ovarian carcinoma or tumor of unknown primary with
paclitaxel and carboplatin. Following her second cycle of carboplatin/Fig. 3.Microscopic view of desmoplastic small round cell tumor on 20× brightﬁeld with
H&E stain.
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vealed EWSR1-WT1 fusion t(11;22)(p13;q12) gene mutation.
At 35w0d gestation, she went for initial consultation with medical
oncology for determination of treatment plan following her pregnancy.
MFM specialists, medical and gynecologic oncology, and her primary
obstetrician made a delivery plan for repeat cesarean delivery at
38 weeks (approximately 3 weeks after cycle 2) with planned comple-
tion hysterectomy, left salpingo-oophorectomy.
The patient underwent a repeat cesarean section. Infant delivered
had APGARs of 9 and 9. She then underwent a total hysterectomy, left
salpingo-oophorectomy, and tumor debulking. Intraoperative ﬁndings
included large tumor plaques on the uterus, small implants on the left
ovary, small peritoneal adhesive disease, as well as large retrocaval
nodal tumor extending superiorly beyond the renal vasculature
resulting in a suboptimal debulking.
Her oncologic care was transitioned to the sarcoma medical oncolo-
gy team. She was initiated on a complex inpatient regimen of vincris-
tine, doxorubicin, cyclophosphamide, with ifosfamide and etoposide.
She remained on this for 12 cycles. Recently her scans showed stable
retroperitoneal nodular disease, and she halted the current chemother-
apy regimen. Further surgical management of residual disease has been
considered along with radiation, and she is currently being maintained
on pazopanib. She is alivewith disease 14months from initial diagnosis.
Comment: This case highlights a rare sarcomatous tumor arising
from the ovary in a pregnant female. Approximately 850 DSRCT have
been reported in the literature (Mora et al., 2015). It was ﬁrst described
as a separate clinical entity in 1989 by case report by Gerald and Rosai,
and conﬁrmed in a case series in 1991 (Gerald et al., 1991). These tu-
mors are similar to other small cell sarcomas including Wilms Tumor
and Ewing sarcoma. However, deﬁnitive diagnosis for this tumor can
be conﬁrmed by ﬂorescence in-situ hybridization (FISH) as DSRCT is
characterized by a unique genetic mutation: EWSR1-WT1 fusion t
(11;22)(p13;q12) (Mora et al., 2015). The tumor is most often found
in the pediatric population, with a male predominance, and patients
are often diagnosed at an advanced stagewith extensive peritonealme-
tastases. Ovarian involvement has been described in the literature
(Nakayama et al., 2013).
One prior case report was found describing DSRCT in pregnancy
(Church et al., 2006). This case was found incidentally at time of cesar-
ean delivery due to arrest of labor. In the presented case, we describe
full antepartummanagement of this rare tumor. DSRCT exhibit aggres-
sive behavior as evidenced in this case by rapid peritoneal spread and
new development of retrocaval adenopathy in the 10 weeks between
primary resection and the time of delivery and secondary surgery de-
spite chemotherapy. Treatment often consists of multi-modal therapy
with surgery and chemotherapy. VAC/IE is a common ﬁrst line regimen,
with a high initial response rate (Kushner et al. 1996). Patients who un-
dergo a complete surgical debulking with chemotherapy have a 3-year
survival of 58% (Lal et al., 2005). Unfortunately, patients who have per-
sistent disease following initial surgery do much worse, with no survi-
vors at 3 years in the same study.Our report highlights three key points to consider. First, the optimal
timing for surgical intervention during pregnancy is during the (early)
second trimester remote from fetal viability. Timely management of a
rapidly enlarging ovarian mass is essential to improving the chance for
an early stage diagnosis of any new ovarian malignancy and improves
the chance of complete resection. Accounting for the extreme rarity of
the tumor presented in our case, we must remember that other types
of primary ovarian neoplasms are not as rare, and patients can beneﬁt
greatly from early surgical care. Second, chemotherapy in pregnancy
can be considered and risks should always be weighed against beneﬁts
of early treatment. Certain platinum based regimens, such as
carboplatin and paclitaxel, are considered safe during the second and
early third trimester (Cardonick and Iacobucci, 2004). Care must be
taken to avoid chemotherapy nadirs (neutropenia, thrombocytopenia)
in themother and the fetus close to delivery, with the last cycle typically
given no later than 35weeks if a termdelivery is anticipated. Finally, ad-
vanced imaging in pregnancy is an option when concern for an adnexal
mass increases. If ultrasound imaging reveals new complexity or con-
siderable growth, MRI is recommended as a safe alternative to CT and
should be promptly acquired.
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